Rapid and Sustained Antidepressant Action of the mGlu2/3 Receptor Antagonist MGS0039 in the Social Defeat Stress Model: Comparison with Ketamine

International Journal of Neuropsychopharmacology

Volumn 20, Issue 3, 2017, Pages 228-236

  Dong, Chao ^a   Zhang, Ji Chun ^a   Yao, Wei ^a   Ren, Qian ^a   Ma, Min ^a   Yang, Chun ^a   Chaki, Shigeyuki ^b   Hashimoto, Kenji ^a  

^a CHIBA UNIVERSITY   (Japan)

^b TAISHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

antidepressant; BDNF TrkB signaling; ketamine; metabotropic glutamate 2 3 (mGlu2 3) receptor antagonist; social defeat stress model; synaptogenesis

Indexed keywords

2 AMINO 3 (3,4 DICHLOROBENZYLOXY) 6 FLUOROBICYCLO[3.1.0]HEXANE 2,6 DICARBOXYLIC ACID; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID RECEPTOR; AMINO ACID RECEPTOR; BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; KETAMINE; POSTSYNAPTIC DENSITY PROTEIN 95; UNCLASSIFIED DRUG; 2-AMINO-3-(3,4-DICHLOROBENZYLOXY)-6-FLUOROBICYCLO(3.1.0)HEXANE-2,6-DICARBOXYLIC ACID; ANTIDEPRESSANT AGENT; BRIDGED BICYCLO COMPOUNDS; DICARBOXYLIC ACID; DISKS LARGE HOMOLOG 4; DLG4 PROTEIN, MOUSE; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR 2; PROTEIN KINASE; TROPOMYOSIN KINASE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; CELL DENSITY; CONTROLLED STUDY; DENDRITIC SPINE; DENTATE GYRUS; DEPRESSION; FORCED SWIM TEST; HIPPOCAMPAL CA3 REGION; LOCOMOTION; MALE; MEDIAL PREFRONTAL CORTEX; MOUSE; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; SINGLE DRUG DOSE; SOCIAL STRESS; SUCROSE PREFERENCE TEST; TAIL SUSPENSION TEST; WESTERN BLOTTING; ANIMAL; ANIMAL BEHAVIOR; BRAIN; COMPARATIVE STUDY; DRUG EFFECT; FOOD PREFERENCE; METABOLISM; TONIC IMMOBILITY;

ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; BRAIN; BRAIN-DERIVED NEUROTROPHIC FACTOR; BRIDGED BICYCLO COMPOUNDS; DENDRITIC SPINES; DICARBOXYLIC ACIDS; DISKS LARGE HOMOLOG 4 PROTEIN; FOOD PREFERENCES; IMMOBILITY RESPONSE, TONIC; KETAMINE; MALE; MICE; PROTEIN KINASES; RECEPTORS, METABOTROPIC GLUTAMATE;

EID: 85021778817     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1093/ijnp/pyw089     Document Type: Article

References (54)

1. Aan Het Rot M, Zarate CA Jr, Charney DS, Mathew SJ (2012) Ketamine for depression: where do we go from here? Biol Psychiatry 72:537-547.
2. Ago Y, Yano K, Araki R, Hiramatsu N, Kita Y, Kawasaki T, Onoe H, Chaki S, Nakazato A, Hashimoto H, Baba A, Takuma K, Matsuda T (2013) Metabotropic glutamate 2/3 receptor antagonists improve behavioral and prefrontal dopaminergic alterations in the chronic corticosterone-induced depression model in mice. Neuropharmacology 65:29-38.
3. Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng PF, Kavalali ET, Monteggia LM (2011) NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475:91-95.
4. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47:e351-e354.
5. Björkholm C, Monteggia LM (2016) BDNF - a key transducer of antidepressant effects. Neuropharmacology 102:72-79.
6. Chaki S, Fukumoto K (2015) Potential of glutamate-based drug discovery for next generation antidepressants. Pharmaceuticals (Basel) 8:590-606.
7. Chaki S, Yoshikawa R, Hirota S, Shimazaki T, Maeda M, Kawashima N, Yoshimizu T, Yasuhara A, Sakagami K, Okuyama S, Nakanishi S, Nakazato A (2004) MGS0039: a potent and selective group II metabotropic glutamate receptor antagonist with antidepressant-like activity. Neuropharmacology 46:457-467.
8. Cryan JF, Holmes A (2005) The ascent of mouse: advances in modeling human depression and anxiety. Nat. Rev. Drug Discov 4:775-790.
9. Dong C, Zhang JC, Yao W, Ren Q, Yang C, Ma M, Han M, Saito R, Hashimoto K (2016) Effects of escitalopram, R-citalopram, and reboxetine on serum levels of tumor necrosis factor-α, interleukin-10, and depression-like behavior in mice after lipopolysaccharide administration. Pharmacol Biochem Behav 144:7-12.
10. Duman RS, Aghajanian GK (2012) Synaptic dysfunction in depression: potential therapeutic targets. Science 338:68-72.
11. Duman RS, Monteggia LM (2006) A neurotrophic model for stress-related mood disorders. Biol Psychiatry 59:1116-1127.
12. Dwyer JM, Duman RS (2013) Activation of mammalian target of rapamycin and synaptogenesis: role in the actions of rapidacting antidepressants. Biol Psychiatry 73:1189-1198
13. Dwyer JM, Lepack AE, Duman RS (2012) mTOR activation is required for the antidepressant effects of mGluR2/3 blockade. Int J Neuropsychopharmacol. 15:429-34.
14. Dwyer JM, Lepack AE, Duman RS (2013) mGluR2/3 blockade produces rapid and long-lasting reversal of anhedonia caused by chronic stress exposure. J Mol Psychiatry 1:15.
15. Fukumoto K, Iijima M, Chaki S (2016) The antidepressant effects of an mGlu2/3 receptor antagonist and ketamine require AMPA receptor stimulation in the mPFC and subsequent activation of the 5-HT neurons in the DRN. Neuropsychopharmacology 41:1046-1056.
16. Golden SA, Covington HE III, Berton O, Russo SJ (2011) A standard protocol for repeated social defeat stress in mice. Nat. Protoc. 6:1183-1191.
17. Hashimoto K (2010) Brain-derived neurotrophic factor as a biomarker for mood disorders: an historical overview and future directions. Psychiatry Clin Neurosci 64:341-357.
18. Hashimoto K (2013) Sigma-1 receptor chaperone and brainderived neurotrophic factor: emerging links between cardiovascular disease and depression. Prog Neurobiol 100:15-29.
19. Hashimoto K (2015) Inflammatory biomarkers as differential predictors of antidepressant response. Int J Mol Sci 16:7796-7801.
20. Karasawa J, Shimazaki T, Kawashima N, Chaki S (2005) AMPA receptor stimulation mediates the antidepressant-like effect of a group II metabotropic glutamate receptor antagonist. Brain Res 1042:92-98.
21. Kishimoto T, Chawla JM, Hagi K, Zarate CA, Kane JM, Bauer M, Correll CU (2016) Single-dose infusion ketamine and non-ketamine N-methyl-D-aspartate receptor antagonists for unipolar and bipolar depression: a meta-analysis of efficacy, safety and time trajectories. Psychol Med 46:1459-1472.
22. Koike H, Chaki S (2014) Requirement of AMPA receptor stimulation for the sustained antidepressant activity of ketamine and LY341495 during the forced swim test in rats. Behav Brain Res. 271:111-115.
23. Koike H, Fukumoto K, Iijima M, Chaki S (2013a) Role of BDNF/TrkB signaling in antidepressant-like effects of a group II metabotropic glutamate receptor antagonist in animal models of depression. Behav Brain Res 238:48-52.
24. Koike H, Iijima M, Chaki S (2011) Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression. Behav Brain Res 224:107-111.
25. Koike H, Iijima M, Chaki S (2013b) Effects of ketamine and LY341495 on the depressive-like behavior of repeated corticosterone-injected rats. Pharmacol Biochem Behav 107:20-23.
26. Lepack AE, Fuchikami M, Dwyer JM, Banasr M, Duman RS (2014) BDNF release is required for the behavioral actions of ketamine. Int J Neuropsychopharmacol 18:pyu033.
27. Li N, Liu RJ, Dwyer JM, Banasr M, Lee B, Son H, Li XY, Aghajanian G, Duman RS (2011) Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol Psychiatry 69:754-761.
28. Liu WX, Wang J, Xie ZM, Xu N, Zhang GF, Jia M, Zhou ZQ, Hashimoto K, Yang JJ (2016) Regulation of glutamate transporter 1 via BDNF-TrkB signaling plays a role in the antiapoptotic and antidepressant effects of ketamine in chronic unpredictable stress model of depression. Psychopharmacology (Berl) 233:405-415.
29. Ma XC, Dang YH, Jia M, Ma R, Wang F, Wu J, Gao CG, Hashimoto K (2013) Long-lasting antidepressant action of ketamine, but not glycogen synthase kinase-3 inhibitor SB216763, in the chronic mild stress model of mice. PLoS One 8:e56053.
30. Maeng S, Zarate CA Jr, Du J, Schloesser RJ, McCammon J, Chen G, Manji HK (2008) Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy- 5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry 63:349-352.
31. McEwen BS (2007) Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol Rev 87:873-904.
32. Monteggia LM, Zarate C, Jr (2015) Antidepressant actions of ketamine: from molecular mechanisms to clinical practice. Curr Opin Neurobiol 30:139-143.
33. Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM (2002) Neurobiology of depression. Neuron 34:13-25.
34. Nestler EJ, Carlezon WA Jr (2006) The mesolimbic dopamine reward circuit in depression. Biol Psychiatry 59:1151-1159.
35. Newport DJ, Carpenter LL, McDonald WM, Potash JB, Tohen M, Nemeroff CB; APA Council of Research Task Force on Novel Biomarkers and Treatments (2015) Ketamine and other NMDA antagonists: early clinical trials and possible mechanisms in depression. Am J Psychiatry 172:950-966.
36. Ohgi Y, Futamura T, Hashimoto K (2015) Glutamate signaling in synaptogenesis and NMDA receptors as potential therapeutic targets for psychiatric disorders. Curr Mol Med 15:206-221.
37. Paucha-Poniewiera A, Wieronska JM, Branski P, Stachowicz K, Chaki S, Pilc A (2010) On the mechanism of the antidepressant-like action of group II mGlu receptor antagonist, MGS0039. Psychopharmacology (Berl) 212:523-535.
38. Ren Q, Ma M, Ishima T, Morisseau C, Yang J, Wagner KM, Zhang JC, Yang C, Yao W, Dong C, Han M, Hammock BD, Hashimoto K (2016) Gene deficiency and pharmacological inhibition of soluble epoxide hydrolase confers resilience to repeated social defeat stress. Proc Natl Acad Sci U S A 113:E1944-E1952.
39. Shirayama Y, Yang C, Zhang JC, Ren Q, Yao W, Hashimoto K (2015) Alterations in brain-derived neurotrophic factor (BDNF) and its precursor proBDNF in the brain regions of a learned helplessness rat model and the antidepressant effects of a TrkB agonist and antagonist. Eur. Neuropsychopharmacol 25:2449-2458.
40. Singh JB, Fedgchin M, Daly EJ, De Boer P, Cooper K, Lim P, Pinter C, Murrough JW, Sanacora G, Shelton RC, Kurian B, Winokur A, Fava M, Manji H, Drevets WC, Van Nueten L (2016) A doubleblind, randomized, placebo-controlled, dose-frequency study of intravenous ketamine in patients with treatment-resistant depression. Am J Psychiatry 173:816-826.
41. Sun HL, Zhou ZQ, Zhang GF, Yang C, Wang XM, Shen JC, Hashimoto K, Yang JJ (2016) Role of hippocampal p11 in the sustained antidepressant effect of ketamine in the chronic unpredictable mild stress model. Transl Psychiatry 6:e741.
42. Witkin JM, Monn JA, Schoepp DD, Li X, Overshiner C, Mitchell SN, Carter G, Johnson B, Rasmussen K, Rorick-Kehn LM (2016) The rapidly acting antidepressant ketamine and the mGlu2/3 receptor antagonist LY341495 rapidly engage dopaminergic mood circuits. J Pharmacol Exp Ther 358:71-82.
43. World Health Organization (2016) Depression. Fact sheet No. 369/April 2016. Available at http://www.who.int/mediacentre/factsheets/fs369/en/index.html. Accessed September 16, 2016.
44. Yang B, Yang C, Ren Q, Zhang JC, Chen QX, Shirayama Y, Hashimoto K (2016a) Regional differences in the expression of brain-derived neurotrophic factor (BDNF) pro-peptide, proBDNF and preproBDNF in the brain confer stress resilience. Eur Arch Psychiatry Clin Neurosci DOI: 10.1007/s00406-016-0693-6.
45. Yang B, Zhang JC, Han M, Yao W, Yang C, Ren Q, Ma M, Chen QX, Hashimoto K (2016b) Comparison of R-ketamine and rapastinel antidepressant effects in the social defeat stress model of depression. Psychopharmacology (Berl) 233:3647-3657.
46. Yang C, Shirayama Y, Zhang JC, Ren Q, Yao W, Ma M, Dong C, Hashimoto K (2015a) R-ketamine: a rapid-acting and sustained antidepressant without psychotomimetic side effects. Transl Psychiatry 5:e632.
47. Yang C, Shirayama Y, Zhang JC, Ren Q, Hashimoto K (2015b) Regional differences in brain derived neurotrophic factor levels and dendritic spine density confer resilience to inescapable stress. Int J Neuropsychopharmacol 18:pyu121.
48. Yilmaz A, Schulz D, Aksoy A, Canbeyli R (2002) Prolonged effect of an anesthetic dose of ketamine on behavioral despair. Pharmacol Biochem Behav 71:341-344.
49. Yoshimizu T, Shimazaki T, Ito A, Chaki S (2006) An mGluR2/3 antagonist, MGS0039, exerts antidepressant and anxiolytic effects in behavioral models in rats. Psychopharmacology (Berl) 186:587-593.
50. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK (2006) A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63:856-864.
51. Zhang JC, Wu J, Fujita Y, Yao W, Ren Q, Yang C, Li SX, Shirayama Y, Hashimoto K (2015a) Antidepressant effects of TrkB ligands on depression-like behavior and dendritic changes in mice after inflammation. Int J Neuropsychopharmacol 18:pyu077.
52. Zhang JC, Yao W, Dong C, Yang C, Ren Q, Ma M, Han M, Hashimoto K (2015b) Comparison of ketamine, 7,8-dihydroxyflavone, and ANA-12 antidepressant effects in the social defeat stress model of depression. Psychopharmacology (Berl) 232:4325-4335.
53. Zhao T, Huang GB, Muna SS, Bagalkot TR, Jin HM, Chae HJ, Chung YC (2013) Effects of chronic social defeat stress on behavior and choline acetyltransferase, 78-kDa glucoseregulated protein, and CCAAT/enhancer-binding protein (C/EBP) homologous protein in adult mice. Psychopharmacology (Berl) 228:217-230.
54. Zhou W, Wang N, Yang C, Li XM, Zhou ZQ, Yang JJ (2014) Ketamineinduced antidepressant effects are associated with AMPA receptors-mediated upregulation of mTOR and BDNF in rat hippocampus and prefrontal cortex. Eur Psychiatry 29:419-423.